TB-500 (Thymosin Beta-4) · Research brief

Where to Buy BPC-157 and TB-500 Research Compounds

Real Peptides Research TeamEditorial

Updated September 24, 20269 min read

55 WORDS

Short answer

Two vials labelled TB-500, ordered from two different suppliers, can contain two genuinely different molecules. One may hold full-length thymosin beta-4, a naturally occurring 43-amino-acid protein of roughly 4.9 kDa. The other may hold a short synthetic fragment built around LKKTETQ, the seven-residue actin-binding motif sitting inside that protein. Same three characters on the label.

Key takeaways

BPC-157 is a 15-amino-acid synthetic peptide with the sequence GEPPPGKPADDAGLV, derived from a partial sequence of a protein found in human gastric juice.
TB-500 sold in research catalogs is usually a fragment built around the LKKTETQ actin-binding motif, not the full 43-amino-acid, roughly 4.9 kDa thymosin beta-4 protein.
Neither peptide is an FDA-approved drug, and both are on the World Anti-Doping Agency Prohibited List, BPC-157 having been added in 2022.
A blend vial is two independent peptides co-lyophilised together, so the certificate of analysis should state both sequences, both purity figures, and the mg split.
Net peptide content is lower than gross vial weight because counterion salt and residual moisture are included in the fill, and honest suppliers disclose both numbers.
Cold-chain condition on arrival predicts material quality more reliably than vendor marketing does, since heat-denatured peptide looks identical to intact peptide.

Our team synthesises research peptides in small batches and reviews third-party analytical data on every lot. This is the single most common point of confusion we hear from laboratories sourcing these two compounds together.

Where to buy BPC 157 TB 500 research compound material?

BPC-157 and TB-500 are supplied by research peptide vendors selling strictly for laboratory use, not by pharmacies, because neither peptide is an approved drug product. The practical filter is documentation, not marketing: a batch-specific certificate of analysis showing HPLC purity and mass-spectrometry identity confirmation. Read the sequence on that certificate before you compare prices.

Here's the oversimplification worth correcting straight away. The blend isn't one compound with one mechanism. It's two structurally unrelated peptides co-lyophilised into a single vial for convenience, each carrying its own preclinical literature, its own stability behaviour, and its own regulatory status. What follows covers what each molecule actually is, what the published research does and doesn't report about studying them together, and the sourcing checks that separate documented material from an anonymous white powder.

What BPC-157 and TB-500 are, molecule by molecule

BPC-157 is a synthetic pentadecapeptide, meaning a chain of 15 amino acids, with the sequence GEPPPGKPADDAGLV. It corresponds to a partial sequence of a protein identified in human gastric juice, which is where the name Body Protection Compound comes from. Its reported stability in acidic conditions is the reason oral research formats exist at all for this peptide, which is unusual: most peptides of this size are degraded rapidly by gastric proteases. Preclinical rodent literature clusters around angiogenesis-related endpoints, with work implicating VEGFR2 signalling and the nitric oxide pathway.

TB-500 is the catalog name for a synthetic peptide corresponding to the actin-binding region of thymosin beta-4, or Tb4. Full-length Tb4 is a 43-amino-acid, roughly 4.9 kDa protein that sequesters G-actin monomers and appears throughout the cell migration and tissue-repair literature. The commercial fragment reproduces the functional motif, not the whole protein. That distinction matters enormously when you're reading papers.

So when someone asks what is BPC 157 and TB 500, the honest answer is that they share almost nothing structurally. One is a 15-residue gastric-derived sequence. The other is a fragment of a cytoskeletal regulatory protein. Labs that buy BPC 157 TB 500 research compound blends are, functionally, running two separate lines of enquiry out of one container.

Why the two get studied together, and what the evidence doesn't show

The pairing exists because the two literatures sit adjacent without overlapping. BPC-157 preclinical work concentrates on vascular and connective tissue models. Thymosin beta-4 work concentrates on actin dynamics, cell migration, and dermal and corneal repair models, including clinical-stage development of Tb4-based formulations by RegeneRx Biopharmaceuticals. Combining them is a mechanistic hypothesis, not a documented finding. We're not aware of a controlled trial evaluating the co-administered blend as a defined product.

Here's the error we see most often, and it isn't a storage error. Researchers compare their fragment-based TB-500 results against published data generated with full-length thymosin beta-4 and treat the two datasets as interchangeable. They aren't. A seven-residue actin-binding fragment and a 43-residue protein have different molar masses, different clearance behaviour, and different receptor-independent interactions. If your certificate of analysis states a sequence and the paper you're citing used recombinant full-length Tb4, you're comparing two different experiments.

Regulatory status is equally unglamorous and equally important. Neither peptide is an FDA-approved drug. The FDA has placed BPC-157 in the Category 2 bulk drug substances grouping under its compounding review, the category flagged for significant safety concerns. The World Anti-Doping Agency prohibits both compounds in sport, with BPC-157 added to the Prohibited List in 2022 and TB-500 listed among prohibited growth factors and peptide hormones. Research suggests promise in animal models. Research suggests is where the sentence has to stop.

How to buy BPC-157 and TB-500 without buying a mystery vial

Anyone planning to buy BPC 157 TB 500 research compound material should evaluate four documents before evaluating four prices. First, a batch-specific certificate of analysis, matched to the lot number printed on the vial, not a generic PDF hosted once and reused across every order. Second, an HPLC chromatogram showing purity, typically stated at 98% or higher for research-grade material. Third, mass-spectrometry identity confirmation matching the expected molecular weight of the stated sequence. Fourth, a clear statement of net peptide content, because gross vial weight includes counterion salt and residual moisture. A vial weighing 10mg gross does not contain 10mg of peptide, and reputable suppliers disclose the difference rather than hide it.

Handling is where otherwise good material dies quietly. Lyophilised peptides are stored frozen for long-term stability; once reconstituted, solutions are refrigerated at 2 to 8 degrees Celsius and treated as short-dated. A temperature excursion during transit can denature peptide structure without changing the appearance of the powder, which is why cold-chain packaging and arrival condition matter more than most buyers assume. Our experience across hundreds of laboratory orders is consistent: the complaints that turn out to be real are almost always shipping-related, not synthesis-related.

One boundary line, stated plainly. These compounds are supplied for laboratory research only and are not for human or veterinary use. If your interest stems from an animal in your care rather than a research project, talk to your veterinarian. Everything here is educational information about research materials, not guidance for use in any living subject.

Separate vials or a co-lyophilised blend: how the material is supplied

The table below compares the three formats in which researchers buy BPC 157 TB 500 research compound material, and what each format costs you in flexibility and documentation clarity.

Supply format	What the vial contains	Flexibility for study design	What the COA must confirm	Bottom line
Separate BPC-157 vial	A single 15-amino-acid peptide, lyophilised, with one molecular weight to verify	Full control over each variable independently	Sequence GEPPPGKPADDAGLV, HPLC purity, MS identity, net peptide content	Cleanest option when either compound is an experimental variable you need to isolate
Separate TB-500 vial	Either a Tb4 fragment or full-length thymosin beta-4, depending entirely on the supplier	Full control, plus you can confirm exactly which molecule you received	Explicit sequence or molecular weight, not just the trade name TB-500	Non-negotiable if you're cross-referencing published thymosin beta-4 data
Co-lyophilised blend vial	Two peptides in one cake, usually at an undisclosed or vendor-set ratio	Lowest, since the ratio is fixed before it reaches you	Both sequences, both purities, and the mg split between them	Convenient only when the ratio is documented; otherwise it's an unquantified mixture

What If: Sourcing and Handling Scenarios

What if the certificate of analysis doesn't list a sequence?

Treat the absence of a stated sequence as a disqualifying gap and request it before ordering. For TB-500 especially, the trade name alone tells you nothing about whether you're receiving a fragment or the full-length protein, and mass-spectrometry identity confirmation is meaningless unless you know which expected molecular weight it was matched against. A supplier publishing lot-linked certificates should produce one within minutes, not days.

What if the shipment arrived warm?

Document the arrival condition photographically, note the lot number, and contact the supplier before opening anything. Lyophilised peptide is more heat-tolerant than reconstituted solution, but tolerance isn't immunity, and thermal denaturation leaves no visual signature in a white cake. Powder that looks perfect can be analytically compromised, which is exactly why arrival condition is a data point worth recording in your lab notes.

What if the blend vial doesn't state the mg ratio of the two peptides?

Don't use it as a quantified input. Without a stated split between BPC-157 and the thymosin beta-4 fragment, any result you generate is unreproducible, because the next vial may carry a different ratio. Researchers who need defined concentrations of each compound should source separate vials and control the composition themselves rather than inheriting an undisclosed formulation decision from a vendor.

What if a supplier describes either compound as FDA-approved or vet-approved?

Walk away, and treat every other claim on that site as suspect. Neither BPC-157 nor TB-500 holds approval as a drug product for humans or animals, and a supplier willing to misstate regulatory status on a public page is unlikely to be rigorous about analytical documentation behind it. Accuracy about what a compound is not is the cheapest available signal of supplier integrity.

The honest answer about blend pricing and synergy claims

Here's the honest answer: the synergy narrative around this pairing is inference, not evidence. Two preclinical literatures pointing at adjacent biology is a reason to design an experiment, not a finding you can cite. Any vendor presenting the combination as a validated whole is selling a story the published record doesn't currently support. The decision to buy BPC 157 TB 500 research compound blends should rest on documentation quality and experimental convenience, nothing more. And blends are frequently priced as though the combination itself adds value. It doesn't. The peptides do.

For laboratories sourcing these compounds individually, our catalog lists BPC-157 10mg and TB-500 10mg as separate lyophilised vials, alongside BPC-157 capsules and the wider oral research compounds range. Background on each molecule sits on our BPC-157 and TB-500 reference pages, lot-linked analytical documents are published in our certificates of analysis library, and the full catalog is available in the shop.

If you take one thing away before you buy BPC 157 TB 500 research compound material, make it this: the label is marketing, the certificate is the product. A vendor can print TB-500 on anything. What they can't fake, not credibly and not repeatedly, is a lot-matched chromatogram and a mass spectrum that agrees with a stated sequence. Ask for both, read the molecular weight, and check it against the molecule the papers you're citing actually used. That one habit separates reproducible research from expensive guesswork.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Both are supplied by research peptide vendors selling for laboratory use only, since neither is an approved drug and pharmacies don't dispense them. Choose suppliers publishing batch-specific certificates of analysis with HPLC purity and mass-spectrometry identity data. Real Peptides supplies both compounds as separate lyophilised vials with lot-linked documentation.

Research-grade BPC-157 and TB-500 come from peptide suppliers operating under research-use-only terms, not clinics or pharmacies. The deciding factor is analytical transparency: a lot-matched certificate showing purity, confirmed molecular weight, and net peptide content rather than gross vial weight. Suppliers who won't produce that certificate before purchase should be avoided entirely.

Verify documentation first, then order. Request the batch-specific certificate of analysis, confirm the stated sequence and molecular weight, check that net peptide content is disclosed separately from gross fill weight, and confirm cold-chain shipping. Purchasing is straightforward once those four checks pass; skipping them is how laboratories end up with unverifiable material.

BPC-157 is a synthetic 15-amino-acid peptide, sequence GEPPPGKPADDAGLV, corresponding to a partial sequence of a protein found in human gastric juice. TB-500 is a synthetic peptide reproducing the actin-binding region of thymosin beta-4, a 43-amino-acid cellular protein. They're structurally unrelated and are studied in separate preclinical literatures.

A blend is simply both peptides co-lyophilised into one vial rather than supplied separately. It's a packaging format, not a distinct compound, and it has no combined pharmacology established in controlled research. The ratio between the two peptides should be stated on the certificate of analysis; if it isn't, the mixture is unquantified.

It's shorthand for the paired sourcing of two research peptides that are frequently ordered together. BPC-157 is a 15-residue gastric-derived sequence. TB500, usually written TB-500, is a thymosin beta-4 fragment built around the LKKTETQ actin-binding motif. The abbreviation describes a purchasing habit, not a single molecule.

Research peptides are sold and purchased for laboratory research use only, and legality depends on jurisdiction and intended use. Neither compound is approved as a drug product, and both are prohibited in competitive sport by WADA. Suppliers, including Real Peptides, supply these materials strictly for research and not for human or veterinary consumption.

Pricing varies widely by supplier, vial size, and whether the material is sold as separate vials or a co-lyophilised blend. The larger variable is what's included: lot-specific analytical testing, mass-spectrometry identity confirmation, and cold-chain shipping all cost money. Unusually cheap material usually reflects missing testing rather than manufacturing efficiency.

No. Neither peptide is an FDA-approved drug product. The FDA placed BPC-157 in the Category 2 grouping of its bulk drug substances review for compounding, the category associated with significant safety concerns. Any supplier describing either compound as FDA-approved or veterinarian-approved is making a false regulatory claim.

They're commonly co-lyophilised together and sold that way, but the format removes your ability to vary each peptide independently. Lyophilised material is stored frozen for long-term stability, and reconstituted solutions are refrigerated at 2 to 8 degrees Celsius. Storing them together also means any stability issue affects both compounds simultaneously.

A blend fixes the ratio between the two peptides before the material reaches your bench, which is convenient but removes a variable from your control. Separate vials cost slightly more in handling time and let you define concentrations yourself. For reproducible work where either compound is a study variable, separate vials are the stronger choice.

It should state the actual amino acid sequence or the confirmed molecular weight, not just the trade name TB-500, because that name is applied to both thymosin beta-4 fragments and full-length protein. Look for HPLC purity, a mass-spectrometry identity result, net peptide content, the lot number, and the test date.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA